Loading clinical trials...
Loading clinical trials...
This is a 10-week trial that evaluates the efficacy and safety of PD 0332334 in subjects, ages from 18 to 65, with generalized anxiety disorder.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT06804525 · Major Depressive Episode (MDE), Major Depressive Disorder (MDD), and more
NCT07429578 · Generalized Anxiety Disorder (GAD), Chronic Insomnia
NCT06661460 · ANXIETY DISORDERS (or Anxiety and Phobic Neuroses), Specific Phobia, and more
NCT05467683 · Obsessive-Compulsive Disorder, Post Traumatic Stress Disorder, and more
NCT06846320 · Generalized Anxiety Disorder (GAD)
Pfizer Investigational Site
Litchfield Park, Arizona
Pfizer Investigational Site
Costa Mesa, California
Pfizer Investigational Site
Pasadena, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions